Nyheter

Forskningsprojekt "SCAPIS" har beviljats stort anslag

Knut och Alice Wallenbergs Stiftelse har beviljat 100 miljoner kronor till forskningsstudien ”SCAPIS”, The Swedish CArdioPulmonary bioImage Study. Studien är nationell och Lars Lind, professor i medicin vid Uppsala universitet, är en av ledarna.

Stort anslag till SciLifeLab och SNP&SEQ-plattformen

SciLifeLab får 200 Mkr från Knut och Alice Wallenbergs stiftelse för att investera i bland annat tio nya sekvenseringsinstrument av typen HiSeq XTen från Illumina. Fem av dessa kommer att installeras hos SNP&SEQ-plattformen på IMV.

Läs mer i pressmedelandet.

Leif Wide får Björkénska priset

Leif Wide, professor emeritus i endokrinologisk biokemi vid Uppsala universitet och upptäckaren av bland annat moderna graviditetstest, har utsetts till mottagare av årets Björkénska pris.

Björkénska priset är ett av Uppsala universitets största vetenskapliga pris för framstående forskning. Det delades ut första gången 1902.

"Den sjukvård vi tar för given kommer förändras i grunden”

Antibiotikaresistensen är en pandemi, men en tyst och långsam sådan. Som en ångvält rullar den fram över världen och hotar att slå ut sjukvården i land efter land. Läs hela artikeln av Björn Olsen, professor i tidningen EXTRAKT, Formas.

Kommande disputationer

  • torsdag, november 13, 2014 13:00 Museum Gustavianum, Akademigatan 3, Uppsala Hambræus, Kristina From Stenting to Preventing: Invasive and Long-term Treatment for Coronary Artery Disease in Sweden. Ladda ner fulltext Mer information
  • torsdag, november 20, 2014 09:15 Enghoffsalen, Entrance 50, Uppsala University Hospital, Uppsala Li, Su-Chen Small Intestinal Neuroendocrine Tumor Analyses: Somatostatin Analog Effects and MicroRNA Profiling. Ladda ner fulltext Mer information

Aktuella publikationer vid institutionen

  • Majeed, A., Hwang, H., Connolly, S., Eikelboom, J., Ezekowitz, M. et al. (2014). Response to Letter Regarding Article, "Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin". Circulation, 130(10): E95-E95 . DOI Mer information
  • Kosunen, T., Pukkala, E., Rautelin, H. (2014). Subsequent Malignancies after Eradication Therapy for Helicobacter Pylori. Helicobacter, 19(S1): 110-111 Mer information
  • Beyder, A., Strege, P., Rainey, J., Bernard, C., Giandomenico, V. et al. (2014). Shear sensitivity of the voltage-gated sodium selective ion channels (NaV) in the neuroendocrine cell line QGP-1. Neurogastroenterology and Motility, 26(S1): 26-26 Mer information
  • Marijon, E., Le Heuzey, J., Connolly, S., Yang, S., Pogue, J. et al. (2014). Response to Letter Regarding Article, "Causes of Death and Influencing Factors in Patients With Atrial Fibrillation: A Competing-Risk Analysis From the Randomized Evaluation of Long-Term Anticoagulant Therapy Study". Circulation, 130(9): E85-E85 DOI Mer information

PIVUS - Prospective Investigation of the Vasculature in Uppsala Seniors

The PIVUS study started in 2001 with the primary aim to investigate the predicive power of different measurements of endothelial function and arterial compliance in a random sample of 1000 subjects aged 70 living in the community of Uppsala. As secondary aims, the study also included measurements of cardiac function and structure by ultrasound and MRI, evaluation of atherosclerosis by ultrasound and MRI, 7 day food intake recordings, detailed ECG analysis, cardiovascular autonomic function, body composition by DXA, DNA analysis and lung function, as well as a number of biochemical markers.

The inclusion of subjects in the study was completed in June 2004 by the team below:

 
          Anna Stenborg, Kerstin Marttala, Lars Lind, Jan Hall

In March 2006 a reinvesigation of the cohort at the age of 75 was started. The major measurements performed at age 70 will be repeated at age 75. In addition, we will focus on infarcts in the brain and heart, so both of these items will be investigated by brain and myocardial MRI in all subjects. Also cognitive tests are included in the reinvestigation that was completed in September 2009.Of the initial 1016 subjects, 52 had died during the 5 years and 827 attended the re-examination at age 75.

In the spring of 2011 we started the 80-year reinvestigation of the cohort. This round will continue until the summer of 2014 and we expect that 500-600 of the original sample will attend. We measure the traditional CV risk factors, 2 cognitive function tests, ultrasound of the carotid arteries and the heart, a DXA scan and an MRI scan of the brain and abdominal region.